Sofia Paul

CellCentric (United Kingdom) — United Kingdom

Medicine · Health Sciences

14h-index3.7kcitations38works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(8), Acute Myeloid Leukemia Research(7), Lung Cancer Diagnosis and Treatment(6), Lung Cancer Treatments and Mutations(6), Estrogen and related hormone effects(6)

Publications38 total

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)
Blood·2025Open Access
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Blood Advances·2025· 4 citedOpen Access
SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy
Clinical Lymphoma Myeloma & Leukemia·2024
AML-347 SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpression
Leukemia & lymphoma/Leukemia and lymphoma·2023· 9 citedOpen Access
PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY
HemaSphere·2023Open Access
Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).
Journal of Clinical Oncology·2023· 2 cited
Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.
Journal of Clinical Oncology·2023· 3 cited
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy
Journal of Clinical Oncology·2023· 166 cited
Targeting <i>RARA</i> overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
Blood Advances·2022· 33 citedOpen Access
Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer.
Journal of Clinical Oncology·2022· 3 cited
Poster: MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
Clinical Lymphoma Myeloma & Leukemia·2021
MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
Clinical Lymphoma Myeloma & Leukemia·2021· 1 cited
Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design
Future Oncology·2021· 33 citedOpen Access
Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood·2020· 4 cited
DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.
Journal of Clinical Oncology·2020· 12 cited
DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2020· 7 cited
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <scp>PANORAMA</scp> 1 trial
British Journal of Haematology·2017· 20 citedOpen Access
Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study
Blood·2014· 5 cited
A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors
Investigational New Drugs·2013· 33 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

David A. Roth(7), Thomas Cluzeau(6), Thorsten Braun(6), Paul G. Richardson(6), Nasser H. Hanna(5), Frances A. Shepherd(5), Pierre Fenaux(5), Eytan M. Stein(5), Michael Kelly(5), Virginia M. Klimek(5), Paul A. Bunn(4), Stéphane de Botton(4), Angela Volkert(4), Kristen Baker(4), Graeme Hodgson(4), Ira Gupta(4), Margaret M. Woo(4), Arnaud Pigneux(4), Pierre Péterlin(4), Frank V. Fossella(3)